Cytomx Therapeutics, INC

CytomX Therapeutics, Inc. announced the immediate appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors.

CytomX Therapeutics and Regeneron Pharmaceuticals have amended their collaboration agreement to extend program selection and add up to eight new cancer therapy programs, with potential milestones reaching $4 billion.

CytomX Therapeutics announced its 2025 financial results and provided updates on its clinical-stage oncology programs, Varseta-M and CX-801.

CytomX Therapeutics announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including progress for CX-2051 and CX-801.

CytomX Therapeutics provided an update on its CX-2051 Phase 1 study, noting a Grade 5 adverse event but confirming continued study execution and enrollment.

CytomX Therapeutics announced its second quarter 2025 financial results, highlighted by positive interim clinical data for CX-2051 in advanced colorectal cancer and a successful $100 million stock offering.

CytomX Therapeutics reported a significant revenue decline and net loss for the third quarter of 2025, but strengthened its financial position with a recent capital raise and advanced key clinical programs.

CytomX Therapeutics reports a significant increase in cash and investments, driven by a recent public offering, while advancing its lead oncology programs CX-2051 and CX-801 despite some collaboration terminations.

CytomX Therapeutics reports increased revenue in Q1 2025 driven by collaboration agreements, while also announcing pipeline prioritization and restructuring efforts to extend cash runway.

CytomX Therapeutics reports a profitable third quarter, driven by increased collaboration revenue and progress in clinical development programs.

CytomX Therapeutics reports a net loss of $6.5 million for Q2 2024, while highlighting advancements in its clinical programs and collaborations.

CytomX Therapeutics reports a strong first quarter of 2024, marked by increased revenue from collaborations and advancements in its clinical programs.

CytomX Therapeutics reports positive early clinical data for Varseta-M and CX-801, alongside a significant net loss and collaboration terminations, while securing capital into Q2 2027.

CytomX Therapeutics' 2024 10-K filing details the company's financial status, pipeline progress, and strategic shift towards prioritized programs and collaborations.

CytomX Therapeutics, a clinical-stage biopharmaceutical company, released its 2023 financial results and provided an update on its pipeline of conditionally activated biologics.

Charles S. Fuchs, a Director of CytomX Therapeutics, Inc., received 118,000 shares of common stock on July 24, 2026.

CFO Christopher Ogden sold 1,624 shares of CytomX Therapeutics to cover tax withholding obligations related to RSU vesting.

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, sold 21,279 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics CEO Sean A. McCarthy sold 118,969 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics' Chief Scientific Officer, Marcia Belvin, sold 31,492 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics' CFO, Christopher Ogden, sold 19,323 shares of common stock to cover tax withholding obligations related to RSU vesting.

CytomX Therapeutics has filed a definitive proxy statement with the SEC.

CytomX Therapeutics is convening its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, and approval of an amended equity incentive plan.

CytomX Therapeutics is supplementing its proxy statement to clarify the number of authorized common shares available for issuance, seeking approval to increase the total from 150 million to 300 million shares.

CytomX Therapeutics, Inc. has filed a definitive proxy statement with the SEC related to its upcoming shareholder meeting.

CytomX Therapeutics is holding its 2024 Annual Meeting of Stockholders on May 15, 2024, to vote on director elections, auditor ratification, an increase in authorized common stock, and executive compensation.

Bank of America Corporation has reported a beneficial ownership of 7.0% in CytomX Therapeutics, Inc., holding over 15.1 million shares.

Seven Fleet Master Fund and associated entities have filed a Schedule 13G reporting a 0.5% beneficial ownership stake in CytomX Therapeutics, Inc.

Longitude Capital and its affiliates have reported a 7% beneficial ownership stake in CytomX Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates report a 4.6% beneficial ownership stake in CytomX Therapeutics, Inc. as of March 31, 2026.

Kynam Capital Management, LP has filed an amendment reporting a 6.9% beneficial ownership stake in CytomX Therapeutics, Inc.

Point72 Asset Management and Steven A. Cohen have reported a 5% beneficial ownership stake in CytomX Therapeutics, Inc.